Bangkok (NNT/VNA) - The Thailand Institute of Nuclear Technology (TINT) has signed a deal with Nagase Thailand to appoint the company as an official reseller of the radiopharmaceuticals product Technetium-99m in Myanmar.
TINT Executive Director Thawatchai Onjun has said that the institute has appointed Nagase Thailand an official reseller of a therapeutic radiopharmaceuticals Technetium-99m in Myanmar, marking the first attempt by Thailand to make a commercial sale of radiopharmaceuticals made in Thailand in a foreign country.
Technetium-99m is a radiopharmaceuticals product commonly used at hospitals in physical examinations. TINT expects the two-year contract for sales in Myanmar will help initiate sales to other countries, especially in the ASEAN region, helping stress the institute’s position as the region’s leader in nuclear technology.
Nagase Thailand’s Managing Director, Kenichi Kurimoto said the company hopes to extend the business beyond Myanmar to other countries, such as Malaysia, as well as ASEAN countries where the company has local offices, in both Laos and Cambodia.
ASEAN countries have previously relied on the importation of radiopharmaceuticals from Japan, South Korea, and European countries, with only limited local manufacturing and sales within the region. TINT is positive made-in-Thailand radiopharmaceuticals will be internationally accepted for their quality./.
TINT Executive Director Thawatchai Onjun has said that the institute has appointed Nagase Thailand an official reseller of a therapeutic radiopharmaceuticals Technetium-99m in Myanmar, marking the first attempt by Thailand to make a commercial sale of radiopharmaceuticals made in Thailand in a foreign country.
Technetium-99m is a radiopharmaceuticals product commonly used at hospitals in physical examinations. TINT expects the two-year contract for sales in Myanmar will help initiate sales to other countries, especially in the ASEAN region, helping stress the institute’s position as the region’s leader in nuclear technology.
Nagase Thailand’s Managing Director, Kenichi Kurimoto said the company hopes to extend the business beyond Myanmar to other countries, such as Malaysia, as well as ASEAN countries where the company has local offices, in both Laos and Cambodia.
ASEAN countries have previously relied on the importation of radiopharmaceuticals from Japan, South Korea, and European countries, with only limited local manufacturing and sales within the region. TINT is positive made-in-Thailand radiopharmaceuticals will be internationally accepted for their quality./.
VNA
